Shares Magazine
Presenting
Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL)
Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease. The Company's lead product candidate, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine.
Thruvision (THRU)
Thruvision Group (THRU) are global providers of fast, safe and respectful people security screening technology for transportation, border control and loss prevention.